* Neuronetics Inc STIM.OQ reported a quarterly adjusted
loss
of 44 cents per share for the quarter ended September 30,
lower than the same quarter last year, when the company reported
EPS of -33 cents. The mean expectation of four analysts for the
quarter was for a loss of 23 cents per share. Wall Street
expected results to range from -26 cents to -20 cents per share.
* Revenue rose 3.6% to $18.53 million from a year ago;
analysts
expected $19.13 million.
* Neuronetics Inc's reported EPS for the quarter was a loss
of 44
cents.
* The company reported a quarterly loss of $13.34 million.
* Neuronetics Inc shares had risen by 44.8% this quarter and
lost 62.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Neuronetics Inc
is 3.00
This summary was machine generated from LSEG data November 12 at
03:29 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.23 -0.44 Missed
Jan. 1 0001 -0.27 -0.33 Missed
Mar. 31 2024 -0.31 -0.27 Beat
Dec. 31 2023 -0.26 -0.19 Beat